| Filed On | Filing |
|---|---|
| 02 Oct 2026 |
8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Submission of Matters to a Vote of Security Holders
1.1 The Board of Directors of CNS Pharmaceuticals, Inc. (the “Company”) established the CNS Pharmaceuticals, Inc. 2020 Equity Plan (the “Plan”) effective as of April 6, 2020, which was approved by the Company’s stockholders at the Compan... |
| 25 Aug 2026 | DEFA14A |
| 21 Aug 2026 |
Proxy statement: annual meeting on September 30, 2026
CEO pay $1.2M, up 5.9% · say-on-pay vote |
| 18 Aug 2026 |
Form 4: Fisher Michal, Director
Bought 2,000 shares ($10K) |
| 18 Aug 2026 |
Form 3: Fisher Michal, Director
No securities owned |
| 18 Aug 2026 |
Form 4: Levin Rami, CEO and President
Disposed of 4,750 shares (Option Exercise/Conversion) · Exercised 4,750 Restricted Stock Units |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | FORM 10-Q FOR JUN 2026 |
| 02 Jul 2026 | 8-K: Regulation FD Disclosure |
| 26 May 2026 | EFFECT |
| 26 May 2026 | 424B3 PROSPECTUS |
| 22 May 2026 | CORRESP |
| 22 May 2026 | UPLOAD |
| 20 May 2026 |
Form 4: Charles Faith L., Director
Bought 7,100 shares ($34K) |
| 19 May 2026 | D |
| 19 May 2026 | FORM S-3 REGISTRATION STATEMENT |
| 15 May 2026 | SCHEDULE 13G/A |
| 14 May 2026 | FORM 10-Q FOR MAR 2026 |
| 04 May 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 30 Apr 2026 | AMENDMENT #1 TO FORM 10-K |
Loading...
